

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

2

Compleat if Known

Application Number	10/601,847
Filing Date	June 23, 2003
First Named Inventor	Martin S. LINSELL
Art Unit	1654
Examiner Name	Not yet assigned

Attorney Docket Number

P-089-US2

U.S. PATENT DOCUMENTS					Class / Subclass
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
JKL	A1	US-4,643,987	02-17-1987	Nagarajan et al.	514/8
JKL	A2	US- 4,698,327	10-06-1987	Nagarajan et al.	514/8
JKL	A3	US- 4,727,064	02-23-1988	Pitha	514/58
JKL	A4	US- 4,983,586	01-08-1991	Bodor	514/58
JKL	A5	US- 5,024,998	06-18-1991	Bodor	514/58
JKL	A6	US- 5,591,714	01-07-1997	Nagarajan et al.	514/9
JKL	A7	US- 5,602,112	02-11-1997	Rubinfeld	514/58
JKL	A8	US- 5,750,509	05-12-1998	Malabarba et al.	514/11
JKL	A9	US- 5,840,684	11-24-1998	Cooper et al.	514/11
JKL	A10	US- 5,916,873	06-29-1999	Cooper et al.	514/9
JKL	A11	US- 6,392,012 B1	05-21-2002	Judice et al.	530/317
JKL	A12	US- 6,444,786 B1	09-03-2002	Judice et al.	530/317
JKL	A13	US- 2002/0055464 A1	05-09-2002	Linsell et al.	514/8

FOREIGN PATENT DOCUMENTS					Class / Subclass
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)			
JKL	B1	WO 94/12217	06-09-1994	Insite Vision Inc.	—
JKL	B2	WO 00/04044	01-27-2000	Princeton University	—
JKL	B3	WO 00/39156	07-06-2000	Advanced Medicine, Inc.	—
JKL	B4	WO 00/54751 (in German with English abstract)	09-21-2000	BASF Aktiengesellschaft	—
JKL	B5	WO 00/59528	10-12-2000	Trustees of Princeton Univ	—
JKL	B6	WO 01/83520 A2	11-08-2001	Advanced Medicine, Inc.	—
JKL	B7	WO 01/97851 A2	12-27-2001	Cubist Pharmaceuticals, Inc.	—
JKL	B8	WO 01/98326 A2	12-27-2001	Advanced Medicine, Inc.	—
JKL	B9	WO 01/98327 A2	12-27-2001	Advanced Medicine, Inc.	—
JKL	B10	WO 01/98328 A2	12-27-2001	Advanced Medicine, Inc.	—
JKL	B11	WO 01/98329 A1	12-27-2001	Advanced Medicine, Inc.	—
JKL	B12	EP 0 667 353 A1	08-16-1995	Eli Lilly and Company	—
JKL	B13	EP 0 816 378 A1	01-07-1998	Eli Lilly and Company	—

Examiner Signature	Jeffrey E. Russell	Date Considered	September 14, 2004
--------------------	--------------------	-----------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

SEP 02 2003

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Complete if Known

Application Number	10/601,847
Filing Date	June 23, 2003
First Named Inventor	Martin S. LINSELL
Group Art Unit	1654
Examiner Name	Not yet assigned

Sheet

2

of

2

Attorney Docket Number

P-089-US2

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
JKL	C1	ALLEN et al., "The Role of Hydrophobic Side Chains as Determinants of Antibacterial Activity of Semisynthetic Glycopeptide Antibiotics", The Journal of Antibiotics, Vol. 50, No. 8, pp 677-684 (1997)	
JKL	C2	GE et al., "Vancomycin Derivatives That Inhibit Peptidoglycan Biosynthesis Without Binding D-Ala-D-Ala", Science, Vol. 284, pp 507-511 (1999)	
JKL	C3	NAGARAJAN et al., "Synthesis and Antibacterial Evaluation of N-Alkyl Vancomycins", The Journal of Antibiotics, Vol. XLII, No. 1, pp 63-72 (1989)	
JKL	C4	NICOLAOU et al., "Chemistry, Biology, and Medicine of the Glycopeptide Antibiotics", Angew. Chem. Int. Ed., Vol. 38, pp 2097-2152 (1999)	
JKL	C5	PAVLOV et al., "A New Type of Chemical Modification of Glycopeptides Antibiotics: Aminomethylated Derivatives of Eremomycin and Their Antibacterial Activity", The Journal of Antibiotics, Vol. 50, No. 6, pp 509-513 (1997)	
JKL	C6	PAVLOV et al., "Chemical Modification of Glycopeptide Antibiotics", Russian Journal of Bioorganic Chemistry, Vol. 24, No. 9, pp 570-587 (1998)	
JKL	C7	PAVLOV et al., "Mono and Double Modified Teicoplanin Aglycon Derivatives on the Amino Acid No. 7; Structure-activity Relationship", The Journal of Antibiotics, Vol. 51, No. 1, pp 73-78 (1998)	
JKL	C8	ZHANG et al., "A review of recent applications of cyclodextrins for drug discovery", Expert Opinion on Therapeutics Patents, Vol. 9, No. 12, 21 pages (1999)	

Examiner Signature

Jeffrey E. Russell

Date Considered

September 14, 2004

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.